Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
187.82
+0.22 (0.12%)
Aug 20, 2026, 10:48 AM EDT - Market open
BDX Revenue
Becton, Dickinson and Company had revenue of $4.98B in the quarter ending June 30, 2026, with 5.44% growth. This brings the company's revenue in the last twelve months to $20.84B, up 5.19% year-over-year. In the fiscal year ending September 30, 2025, Becton, Dickinson and Company had annual revenue of $21.84B with 8.24% growth.
Revenue (ttm)
$20.84B
Revenue Growth
+5.19%
P/S Ratio
2.27
Revenue / Employee
$312,278
Employees
72,000
Market Cap
51.16B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 21.84B | 1.66B | 8.24% |
| Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
| Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
| Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
| Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
| Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
| Sep 30, 2019 | 17.29B | 1.31B | 8.18% |
| Sep 30, 2018 | 15.98B | 3.89B | 32.17% |
| Sep 30, 2017 | 12.09B | -390.00M | -3.12% |
| Sep 30, 2016 | 12.48B | 2.20B | 21.41% |
| Sep 30, 2015 | 10.28B | 1.84B | 21.74% |
| Sep 30, 2014 | 8.45B | 392.00M | 4.87% |
| Sep 30, 2013 | 8.05B | 346.00M | 4.49% |
| Sep 30, 2012 | 7.71B | 124.00M | 1.64% |
| Sep 30, 2011 | 7.58B | 459.62M | 6.45% |
| Sep 30, 2010 | 7.12B | 137.66M | 1.97% |
| Sep 30, 2009 | 6.99B | 89.10M | 1.29% |
| Sep 30, 2008 | 6.90B | 614.78M | 9.79% |
| Sep 30, 2007 | 6.28B | 544.82M | 9.49% |
| Sep 30, 2006 | 5.74B | 397.18M | 7.44% |
| Sep 30, 2005 | 5.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medline | 29.94B |
| Baxter International | 11.47B |
| Intuitive Surgical | 11.03B |
| Alcon | 10.86B |
| Solventum | 8.31B |
| Avantor | 6.56B |
| ResMed | 5.65B |
| The Cooper Companies | 4.23B |
BDX News
- 2 days ago - Becton Dickinson names Gary Sorsher as Chief Quality Officer - TheFly
- 2 days ago - BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire - PRNewsWire
- 3 days ago - Becton Dickinson completes enrollment in PREVENT trial - TheFly
- 3 days ago - Becton Dickinson price target raised to $208 from $204 at Citi - TheFly
- 3 days ago - Becton Dickinson price target raised to $190 from $180 at RBC Capital - TheFly
- 8 days ago - BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial - PRNewsWire
- 13 days ago - Becton Dickinson price target raised to $195 from $175 at Stifel - TheFly
- 13 days ago - Becton Dickinson price target raised to $180 from $175 at RBC Capital - TheFly